怡达股份：控股子公司拟2456.5万元收购万淇生物科技（泰州）有限公司85%股权

Core Viewpoint - Yida Co., Ltd. plans to acquire 85% equity of Wanquan Biotechnology (Taizhou) Co., Ltd. from Wanquan Co., Ltd. for 24.565 million yuan, aiming to enhance its production capacity and product line in the fine chemical sector [1] Group 1 - The acquisition will make Wanquan Biotechnology a subsidiary of Yida Co., Ltd. [1] - The purpose of the acquisition is to leverage Wanquan's production experience and sales channel advantages [1] - The collaboration aims to promote the construction and investment of epoxy propylene (ethylene) derivatives in the fine chemical field [1] Group 2 - The transaction is expected to optimize Yida's capacity layout and enrich its product offerings [1] - The acquisition is intended to effectively meet downstream customer demands [1]